1 unknown. .
Follow Wenbin Wei: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-VEGF in Real-world Ranibizumab, Aflibercept, Conbercept - Neovascular Age-related Macular Edema, Diabetic Macular Edema | Unknown | Wenbin Wei | 1000 | 2022-01-01 | 2022-02-03 |
KH902 fusion protein (1) · Ranibizumab (1) · aflibercept (1)
China (1)